Herb & supplement monograph

Antineoplastons Drug Interactions, Uses, Effectiveness, Safety & More

Medically reviewed by ·Updated July 2026
What is this page for?

First and foremost: how Antineoplastons interacts with medications. The heart of this page is the interaction list — every drug Antineoplastons is known to interact with, and how serious each one is.

But these pages have grown well beyond that into a full monograph — what Antineoplastons is, what people use it for and how strong the evidence is, its safety and side effects, and answers to the questions we’re asked most — written and reviewed by the clinical staff at HelloPharmacist. It’s educational information from our licensed clinical databases, not medical advice, and we don’t sell or endorse products. Our editorial policy

Check Antineoplastons against your medication

Add one medication
Antineoplastons
+
Start typing any prescription or over-the-counter drug name.
Reviewed by licensed pharmacists Sourced from Natural Medicines
On this page
Interaction report

Drugs that interact with Antineoplastons

0 medications have a known interaction with Antineoplastons, graded by severity. Select any drug for the full evidence-based detail.

We don’t currently list any known drug interactions for Antineoplastons. This doesn’t guarantee none exist — always confirm with your pharmacist before combining supplements with your medications.

Read The List Like a Pharmacist

What Severity, Likelihood & Evidence Mean

Severity — How Serious It Can Be

  • Major. Clinically significant; generally best avoided, or used only under direct professional supervision.
  • Moderate. May need monitoring, a dose adjustment, or separating the times you take each one.
  • Minor. Generally not clinically significant, but still worth noting and mentioning to your pharmacist.
  • No known interaction. Checked against our sources with nothing documented — not the same as proven safety.

Likelihood — How Well It’s Documented

  • Likely. Well-controlled human studies have demonstrated the likely existence of this interaction
  • Probable. Interaction has not been documented in well-controlled studies, however, the interaction has been demonstrated in some small human studies or in controlled animal studies in conjunction with multiple case reports.
  • Possible. Interaction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
  • Unlikely. Interaction has been demonstrated in animal or in lab research but has been shown not to occur in humans.

Where This Data Comes From

  • Interaction records are evidence-graded and sourced from the Natural Medicines database (TRC Healthcare), the same reference used by pharmacists and hospitals.
  • Each drug listed above links to the full report for that exact Antineoplastons combination — clinical detail, likelihood, evidence level, and citations.
  • Content is reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Monograph

Antineoplastons: Uses, Safety & Side Effects

Medically reviewed by · Reviewed July 2026 ·
The bottom line

Antineoplastons are synthetic peptide and amino acid compounds promoted as an alternative cancer treatment, but they are not approved by the FDA and high-quality clinical evidence supporting their effectiveness is lacking. Most studies have been conducted by their developer and have not been independently confirmed. If you are considering them, talk with your oncologist first, and never replace proven cancer treatment with an unproven one.

Part used
Synthetic peptides, amino acid derivatives, and organic acids (originally isolated from human blood and urine)
Common forms
Oral capsules and intravenous (IV) infusions, used mainly within specific clinics or research settings
People commonly use it for
  • Cancer (various types, including brain tumors)
  • Adjunct cancer support
  • Investigational anticancer therapy

Popular and traditional uses — not proof it works. See “Uses & effectiveness” below for the evidence.

Safety at a glance
OverallUse caution

Not FDA-approved; effectiveness is unproven and side effects can be serious, especially at high doses.

PregnancyInsufficient reliable information

Insufficient reliable information available; avoid using.

Read the full pregnancy detail
BreastfeedingInsufficient reliable information

Insufficient reliable information available; avoid using.

Read the full breastfeeding detail

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center). Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Jump to a section

Overview

Antineoplastons are a group of compounds made up of peptides (small pieces of protein), amino acid derivatives, and organic acids. They were first described in the 1970s by a physician who noticed that certain substances seemed to be present in healthy people but lower in people with cancer. This led to the idea that these substances might help fight tumors.

The compounds were originally separated from human blood and urine, but today they are made synthetically. They go by names such as Antineoplaston A, A2, A3, A5, A10, and AS2-1. They are not herbs or plants — they are lab-made chemical mixtures.

Antineoplastons are mainly associated with a specific clinic and have been used as an alternative or experimental cancer treatment, sometimes through clinical trials. They are not approved by the U.S. Food and Drug Administration (FDA) for treating any disease.

How it works

The proposed idea is that antineoplastons act as part of a natural "biochemical defense system" that helps the body control abnormal cell growth. Supporters suggest these compounds may help cancer cells mature into more normal cells (called differentiation), turn off genes that drive cancer growth (oncogenes), and slow down the multiplication of cancer cells.

It is important to understand that these mechanisms come mostly from laboratory and animal research. They have not been clearly confirmed in well-run human studies, and it is not certain that they happen in a meaningful way in people with cancer.

Effectiveness

Does Antineoplastons work?

Here’s what the research actually shows for each use — graded by Natural Medicines and reviewed by .

Evidence overview · 4 uses evaluated
4 Insufficient evidence
How to read these evidence grades

Natural Medicines’ 7-point scale. We show each rating’s label word-for-word.

1EffectiveStrong, consistent evidence it works.
2Likely EffectiveGood evidence, though not yet conclusive.
3Possibly EffectiveSome evidence suggests a benefit.
4Possibly IneffectiveSome evidence it may not help.
5Likely IneffectiveFairly strong evidence it doesn’t help.
6IneffectiveStrong evidence it doesn’t work.
7Insufficient Reliable Evidence to RateToo little research to say either way.

For Antineoplastons, current evidence isn’t strong enough to rate any specific use. The conditions it has been studied for are listed below.

Also studied for 4 conditions — evidence insufficient to rate
Insufficient Reliable Evidence To Rate Brain tumor
Rating & evidence shown verbatim from Natural Medicines

Some limited evidence suggests that antineoplastons might help achieve complete or partial response in some patients with various types of brain tumors. However, all of this research suffers from small size, poor study design, and the lack of a comparator group. At this time, there isn't enough reliable evidence to support using antineoplastons for any type of cancer.

Insufficient Reliable Evidence To Rate Colorectal cancer
Rating & evidence shown verbatim from Natural Medicines

Preliminary clinical research in adults who have undergone hepatectomy due to metastatic colorectal cancer shows that intravenous administration of antineoplastons A10 and AS2-1, in conjunction with hepatic arterial infusion of 5-fluorouracil, increases average cancer-specific survival from 39 months to 67 months, but does not reduce relapse-free survival, when compared with receiving 5-fluorouracil alone. Tell patients there isn't enough reliable evidence to support using antineoplastons for any type of cancer.

Sources Ref 99812
Insufficient Reliable Evidence To Rate Primitive neuroectodermal tumor (PNET)
Rating & evidence shown verbatim from Natural Medicines

In pediatric patients at high-risk for PNETs, preliminary clinical research shows that administering a combination of antineoplastons A10 and AS2-1 as intravenous infusions for 1.2 to 67 months results in complete response in 23% of patients, partial response in 8% of patients, stable disease in 31% of patients, and disease progression in 38% of patients. This research suffers from poor study design and the lack of a comparator group. Tell patients there isn't enough reliable evidence to support using antineoplastons for any type of cancer.

Sources Ref 25611
Insufficient Reliable Evidence To Rate Prostate cancer
Rating & evidence shown verbatim from Natural Medicines

Preliminary clinical research shows that administering AS2-1 along with diethylstilbestrol 0.01-0.02 mg/kg daily to patients with prostate cancer results in complete remission in 14% of patients, partial remission in 22% of patients, disease stabilization in 50% of patients, and disease progression in 14% of patients. This research suffers from poor study design and the lack of a comparator group. Tell patients there isn't enough reliable evidence to support using antineoplastons for any type of cancer.

Sources Ref 20102

Source & disclaimer. Effectiveness ratings and evidence summaries are provided by Natural Medicines (Therapeutic Research Center) and shown as licensed. Where Natural Medicines hasn’t rated a use, HelloPharmacist’s pharmacists may add their own reviewed rating and evidence (each such entry is labeled). This is educational information, not medical advice — talk with your pharmacist or doctor before starting, stopping, or changing a supplement.

Safety & precautions

Antineoplastons are not FDA-approved, and their safety has not been firmly established. They have been linked to side effects that can become serious, especially with the high doses sometimes used.

People with heart, kidney, or liver problems, and anyone who is dehydrated or has trouble handling extra salt or fluid, should be especially careful. Children may be more vulnerable to certain side effects.

Pregnancy and breastfeeding: There is no reliable safety information for these situations. Because of this uncertainty and the possibility of harm, antineoplastons should be avoided during pregnancy and breastfeeding.

Always talk with your oncologist or pharmacist before using any unproven cancer treatment. Choosing an unproven therapy instead of proven care can be dangerous.

Side effects

Reported side effects include headache, nausea, vomiting, tiredness, rash, and confusion. Because some forms contain a lot of sodium, they can cause high blood sodium levels (hypernatremia), swelling, increased thirst, and excessive urination.

More serious problems that have been reported include severe neurological symptoms, brain swelling, and seizures, particularly with high IV doses. Allergic reactions and blood chemistry imbalances are also possible. These effects can be life-threatening and require medical care.

Antineoplastons: Reported Adverse Effects

Documented safety reports on Antineoplastons from the evidence-graded Natural Medicines (TRC Healthcare) database, shown word-for-word from the licensed record.

Adverse effects to antineoplastons have been reported in several small clinical studies. It is not clear how common these reactions are, or if they occur more frequently than with placebo. Since many patients taking antineoplastons have been diagnosed with serious illnesses, such as advanced cancers, it is not clear if these effects resulted from the illnesses themselves or were caused by antineoplastons. Adverse effects include sore throat, fever, chills, reduced albumin, increased amylase, hypoglycemia, hypokalemia, eosinophilia, increased alkaline phosphatase, and a strong body odor similar to urine. Antineoplastons have also been associated with finger rigidity, as well as metabolic/electrolyte abnormalities.

  1. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249.
  3. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  4. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
  5. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
Reports by condition
Anemia Hematologic

Orally and intravenously, decreased bone marrow activity has been reported for patients treated with chemotherapy along with antineoplaston A10 or antineoplaston AS2-1; however, this effect has not been observed for patients treated with these antineoplastons without chemotherapy.

Intravenously, antineoplastons A10 and AS2-1 have been associated with anemia and lowered white blood cell counts in patients with brain tumors. Decreases in white blood cell and platelets have also been reported for patients treated with A10, AS2-1 and A10-1. However, increases in white blood cells and platelets have also been reported for patients treated with antineoplaston A or antineoplaston AS2-1.

Intravenously, hypernatremia has been reported for patients with brain stem glioma treated with antineoplastons AS10 and AS2-1. In one study, 3 of 17 patients experienced hypernatremia; one patient developed grade 4 hypernatremia.

  1. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249.
  3. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
  4. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177.
  5. Burzynski SR, Janicki TJ, Weaver RA, Burzynski B. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther. 2006 Mar;5(1):40-7.
  6. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367.
  7. Burzynski SR, Stolzmann Z, Szopa B, Stolzmann E, Kaltenberg OP. Antineoplaston A in cancer therapy. (I). Physiol Chem Phys 1977;9(6):485-500.
  8. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  9. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst. 2014 D
Bladder cancer Cardiovascular

Intravenously, antineoplaston A5 has been associated with palpitations at doses up to 153 mg/kg daily. A 71 year-old male bladder cancer patient experienced chest pressure and irregular heartbeat after receiving intravenous antineoplaston A5 58 mg/kg/day for 5 days. Use of intravenous antineoplaston AS2-1, up to 160 mg/kg daily for over 2 years, has been associated with mild hypertension. Tachycardia occurred in one of 24 patients diagnosed with neoplastic diseases who were given intravenous antineoplaston A3, up to 76 mg/kg daily for up to 1.3 years.

  1. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  2. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  3. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249.
  4. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  5. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
Cluster headache Neurologic/CNS

Orally and intravenously, headache, fatigue, sleepiness, ringing in the ears, and numbness have been reported for patients treated with antineoplastons A10 and AS2-1. Dizziness has also been noted for some patients treated with oral antineoplaston A10 or intravenous antineoplaston A3.

  1. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145.
  2. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
  3. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
  4. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326.
  5. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  6. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  7. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
Fatigue Musculoskeletal

Orally and intravenously, antineoplastons AS2-1 and A10 have been associated with peripheral edema. Swelling of joints, muscle and joint pain, muscle contractions in the throat, weakness, and fatigue have been reported for patients treated with antineoplastons A2, AS2-1, AS2-5, and/or A10.

  1. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249.
  2. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
  3. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
  4. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  5. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
Fever Other

Intravenously, fever has been reported in patients receiving 6 months of treatment with A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily).

  1. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
  2. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
Flatulence Gastrointestinal

Orally, nausea, vomiting, upset stomach, abdominal pain, and excessive flatulence has been reported for patients with neoplastic disease treated with antineoplaston A10 100-149 mg/kg/day for up to 149 days.

  1. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  2. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
Myasthenia gravis Dermatologic

Intravenously, mild maculopapular allergic-type rash has been noted in patients receiving antineoplaston AS2-1, up to 160 mg/kg daily for up to 2.4 years. During 6 months of intravenous bolus injections of A10 (11.3 grams/kg daily) and AS2-1 (0.4 grams/kg daily), three cases of skin rash were reported for patients with recurrent brain stem glioma. Mild pruritus has been observed in two patients undergoing therapy with A10, AS2-1, and A10-1. Redness of hands and feet has been noted for patients injected with AS2-5.

  1. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  2. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101.
  3. Kumabe T, Tsuda H, Uchida M, et al. Antineoplaston treatment for advanced hepatocellular carcinoma. Oncol Rep 1998;5(6):1363-1367.
  4. Burzynski SR. Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:17-24.
DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.

Adverse-effects data: Natural Medicines, Therapeutic Research Center

Dosing

There is no established, standardized safe dose of antineoplastons for any condition, and they are not available as a regular over-the-counter supplement. The doses studied have varied widely and were given under medical supervision, often as intravenous infusions.

Because these products are unproven and can cause serious side effects, you should not try to dose them on your own. If you are considering antineoplastons, discuss it thoroughly with your oncologist and pharmacist first.

Pregnancy & Breastfeeding

Antineoplastons & Pregnancy

Insufficient reliable information

Insufficient reliable information available; avoid using.

Antineoplastons & Breastfeeding

Insufficient reliable information

Insufficient reliable information available; avoid using.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.

© 2026 Therapeutic Research Center

Pregnancy & lactation ratings: Natural Medicines, Therapeutic Research Center

References & further reading

The 20 references that drive our Antineoplastons monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Burzynski SR, Stolzmann Z, Szopa B, Stolzmann E, Kaltenberg OP. Antineoplaston A in cancer therapy. (I). Physiol Chem Phys 1977;9(6):485-500.
  2. Burzynski SR, Mohabbat MO, Burzynski B. Human toxicology studies on oral formulation of Antineoplaston A10. Drugs Exp Clin Res 1984;10(12):891-909.
  3. Burzynski SR, Kubove E, Burzynski B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exp Clin Res 1990;16(7):361-369.
  4. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999;74(2):137-145. PubMed
  5. Burzynski SR, Conde AB, Peters A, et al. A retrospective study of antineoplastons A10 and AS2-1 in primary brain tumors. Clin Drug Invest 1999;18(1):1-10.
  6. Burzynski SR, Lewy RI, Weaver RA, et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 2003;4(2):91-101. PubMed
  7. Tsuda H, Hara H, Eriguchi N, et al. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 1995;42(4):241-249. PubMed
  8. Burzynski SR, Kubove E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 1987;13 Suppl 1:17-29.
  9. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
  10. Burzynski SR, Weaver RA, Lewy RI, et al. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report. Drugs R D 2004;5(6):315-326. PubMed
  11. Burzynski SR, Weaver RA, Janicki T, et al. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 2005;4(2):168-177. PubMed
  12. Burzynski SR, Burzynski B, Mohabbat MO. Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:25-35.
  13. Burzynski SR, Kubove E. Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 1986;12 Suppl 1:47-55.
  14. Burzynski SR, Kubove E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years' follow-up. Drugs Exp Clin Res 1987;13 Suppl 1:1-11.
  15. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13 Suppl 1:37-43.
Keep reading

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Pharmacist Counseling Corner

Antineoplastons: Common Questions

What is Antineoplastons used for, and does it work?
People use Antineoplastons for a range of reasons, but according to the Natural Medicines database the current clinical evidence is insufficient to confirm it works for the specific conditions it has been studied for. See the graded list on this page, and talk to your pharmacist or doctor before relying on it for any condition.
Does Antineoplastons interact with prescription medications?
We do not currently list any known drug interactions for Antineoplastons. This does not guarantee that none exist, so always confirm with your pharmacist before combining it with your medications.
How are Antineoplastons interactions rated?
Each interaction is graded major, moderate, or minor based on how clinically significant it is and the strength of the evidence behind it. Major interactions are the most serious and are best avoided, or used only under close professional supervision.
Is it safe to take Antineoplastons with my medications?
It depends on the specific medication. Some combinations are fine, while others call for monitoring, timing changes, or should be avoided. Check your exact drug above and confirm with your pharmacist or doctor before starting, stopping, or changing anything.
Where does this Antineoplastons interaction information come from?
Our interaction data is built on the Natural Medicines database — an evidence-graded reference for vitamins, herbs, and supplements — and is reviewed by licensed HelloPharmacist pharmacists, who may add clinical context.
What are Antineoplastons used for?
They are promoted mainly as an alternative or experimental cancer treatment, including for brain tumors. However, they are not FDA-approved and there is no strong, independent evidence that they work.
Are Antineoplastons a proven cancer cure?
No. Despite many years of use and study, there is no reliable, high-quality evidence that they cure or control cancer, and they are not part of standard cancer care.
Are Antineoplastons safe?
Their safety is not well established. They can cause side effects ranging from nausea and high sodium levels to serious neurological problems, especially at high doses.
Can I use Antineoplastons instead of chemotherapy or radiation?
You should not replace proven cancer treatments with Antineoplastons. Doing so can be dangerous and may allow the cancer to grow. Always discuss any treatment decision with your oncologist.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next
Supplement interaction checkerCheck any supplement or product against your medications Drug–drug interactionsCheck two or more of your medications against each other Browse medications A–ZEvery drug we’ve checked against herbs & supplements NDC & pricing lookupFind a drug’s NDCs, packaging and costs Ask a pharmacistFree, personal answer from our licensed team

Have a question about Antineoplastons?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist